What's it Worth? A Journal Club Podcast

Welcome back to What's it Worth! Join your hosts, Dr. Diana Langworthy and Dr. Garrison Avery (PGY1 Pharmacy Resident), as we discuss the STOP ACEi trial comparing continuation of ACEi/ARB ( a ngiotensin c onverting e nzyme i nhibitors/ a ngiotensin r eceptor b lockers) therapy in ESKD vs discontinuation of ACEi/ARB therapy. The authors sought to answer the question - Does discontinuation vs conti...

Episode 2 of the Double Header  with the  Minnesota Twins ! The first article, the SEQUOIA trial, was discussed in the preceding episode with Mckay Carstens... did you guess correctly for which twin was speaking? He's passing the baton to his brother Kane to discuss management of portal hypertension in patients with cirrhosis. We're looking back in time with a retrospective study that investigated...

Join us for a Double Header with the Minnesota Twins ! No, we haven't converted to a sports podcast... I have PGY1 Residents (who are identical twins), Kane and Mckay Carstens joining me for back-to-back journal critiques! The first article, the SEQUOIA trial, was conducted to determine the efficacy and safety of aficamten, a novel cardiac myosin inhibitor, in patients with obstructive Hypertrophi...

Welcome to What's it Worth! Join your host, Dr. Diana Langworthy and student guest host, Meade Avery , as we walk the tightrope of anticoagulation in elderly patients with Atrial Fibrillation (AFib). We'll be reviewing an article that evaluated frail, elderly patients with AFib and compared maintaining INR guided warfarin with switching to a direct acting oral anticoagulant (DOAC). Come along as w...

Welcome to  What's it Worth! Join your host Dr. Diana Langworthy, with student co-host Rachel Cohen, as we hit the design dictionary to decode statistical language and simplify estimands and populations. Our expert guest for this episode is Dr. Kylee Funk, Assoiate Professor and Ambulatory Care Pharmacist. We're discussing a trial that compared oral semaglutide with subcutanous liraglutide, GLP-1...

Welcome to  What's it Worth! Join your host Dr. Diana Langworthy as we record  live with our 2nd year Pharmacy Students for their EBP Pulse Check! We're exploring whether or not we should REDUCE our use of beta blockers in post MI patients who have a preserved ejection fraction by critiquing the REDUCE-AMI trial (NEJM 2024). Our expert guest for this episode is Dr. Anne Schullo-Feulner, Clinical P...

Welcome to What's it Worth! Join your host Dr. Diana Langworthy and guest host Rachel Cohen (PharmD Candidate, 2025) as we take a look at how cannabis affects pregnancy outcomes.  Our guest, Dr. Ann Philbrick, PharmD, BCACP, will share her expertise with the current state of cannabis use and what it looks like to see patients who use cannabis in pregnancy. Key Points Existing evidence regarding ca...

Welcome back to What's it Worth! Join your hosts, Dr. Diana Langworthy and P4 Garrison Avery, as we discuss the RENAL-AF trial comparing apixaban vs warfarin in hemodialysis patients.  These authors aimed to assess safety and efficacy in one of the first prospective trials comparing DOACs with warfarin in hemodialysis patients. Ever read a trial that didn't enroll their goal number of patients? Le...

Welcome back to What's it Worth! Join your hosts, Dr. Diana Langworthy and Garrison Avery, student PharmD, as we evaluate the 52 week reported outcomes of the ongoing Resmetirom Phase 3 trial. This trial is our first look at a medication currently seeking FDA approval to halt and reverse NASH and liver fibrosis. We also discuss Bonferroni statistical analysis, patients excluded from the trial, and...

Did you miss us? We're back for Season 2 of What's it Worth! Join your host, Dr. Diana Langworthy, and co-host Garrison (Griest) Avery (back at the end of his APPE year for some more EBP fun!), as they find out if phenobarbital is beating benzos in severe alcohol withdrawal!  CI-WAt all the fuss is about in season two as we PAWSS and reflect on where single-site retrospective results and clinical...

Welcome to  What's it Worth - BONUS episode #2! Join your host Dr. Diana Langworthy and a come-back by P4 student co-host Marina Fahim as we get biosimilar! Our expert guest for this episode is Dr. Hannah Berg, Formulary Management Pharmacist at United Healthcare. We're discussing a trial that aimed to determine whether pegfilgrastim biosimilars were considered statistically equivalent to the pegf...

Welcome to  What's it Worth - a BONUS episode! Join your host Dr. Diana Langworthy and a come-back by P4 student co-host Garrison Griest as we get the scoop on poop! Our expert guest for this episode is Dr. Jen Ross, Antimicrobial Stewardship Clinical Pharmacist at M Health Fairview East and West Bank Hospitals. We're discussing a trial that evaluated the efficacy of a new orally administered feca...

Welcome to  What's it Worth! Join your host Dr. Diana Langworthy as we co-mingle with co-primary clues! Our expert guest for this episode is  Dr. Natalie Heinrich, Medication Therapy Management Clinical Pharmacist in Neurology at M Health Fairview. We're discussing a trial evaluated the efficacy of zavegepant, a novel CGRP antagonist for nasal administration, for the treatment of acute migraine at...

Welcome to  What's it Worth! Join your host Dr. Diana Langworthy, & co-host Marina Fahim, as we ATTACK the critique of a non-inferiotiy study design. Our expert guest for this episode is Dr. Betsy Hirsch, Assoiate Professor and Infectious Diseases Translational Researcher. We're discussing a trial that compared a new beta-lactam antibiotic, sulbactam/durlobactam, with colistin for the treatment of...

Welcome to  What's it Worth! Join your host, Dr. Diana Langworthy and co-host  Chelsea Bolier, PharmD, as we break down Delphi and learn more about analyzing qualitatitve data.  We're joined this month by  Dr. Joel Farley, PhD and Dr. Pamela Phelps, PharmD, FASHP -  two experts in the arena of determining the impact of clinical pharmacy services.    Key Points Determining the impact of clinical ph...

Welcome to  What's it Worth! Join your hosts, Dr. Diana Langworthy & Garrison Griest as we go retro to tackle confounding variables! We'll be reviewing an article that aimed to determine the risk of spontaneous bacterial peritonitis (SBP) in patients with cirrhosis who are using proton pump inhibitors (PPIs).   Key Points Retrospective studies produce more opportunities for confounding variables t...

08Welcome to What's it Worth! Join your hosts, Dr. Diana Langworthy, Nathan Uk, and Garrison Griest as we walk you through composite outcomes with the CLEAR trial - a comparison of bempedoic acid versus placebo for preventing major adverse cardiovascular events (MACE) in patients who cannot tolerate statin therapy. We're joined by  Dr. Chrystian Pereira ,  PharmD, BCACP,  an ambulatory care pharma...

Welcome to What's it Worth! Join your hosts, Dr. Diana Langworthy, Nathan Uk, and Garrison Griest as we take on the evidence behind a trending treatment for COVID-19.  Our guest, Dr. Ann Philbrick, PharmD, BCACP, will share her expertise with medical cannabis products to help figure out what is TBD about CBD in COVID-19.     Key Points Cannabidiol (CBD) has some purported anti-inflammatory propert...

Welcome to What's it Worth! Join your host, Dr. Diana Langworthy as we're strengthening our EBP skills in power and subject allocation with the STRONG-HF trial - a prospective, randomized, open-label study comparing high-intensity titration to guideline-directed medical therapy vs usual cares in patients with recent heart failure exacerbations.  Special guest - Dr. Christian Bell, PharmD and PGY1...

Welcome to What's it Worth! Join Dr. Diana Langworthy, Garrison Griest, and Nathan Uk for our first episode where we go down the WATERFALL and take a deep dive into the details of a prospective, open-label trial comparing aggressive and moderate fluid resuscitation strategies in the initial treatment of acute pancreatitis. Key Points Aggressive fluid resuscitation has historically been preferred i...

BONUS EPISODE! We're dropping Episode 2 early so you have even more journal critique music to your ears. Welcome back to What's it Worth! Today we soar through the topics of pilot studies, medical cannabis, and cancer related pain. We are joined by Dr. Kirollos Hanna, Director of Pharmacy at Minnesota Oncology, as we attempt to take the pain out of assessing feasibility trials.   Key Points Pilot...